Investment Bank Ratings & Recommendations
Report Date: 2026-03-11
⚡ Key Takeaways
📈 Notable Upgrades 5 calls
INTC
Intel Corporation
↑ Upgrade
Goldman Sachs • Toshiya Hari 📅 2026-03-10
Neutral → Buy
Old PT $52.00
New PT $58.00
Current $46.78
24.0%
18A foundry progress and Lunar Lake ramp positioning Intel for datacenter recovery
META
Meta Platforms, Inc.
↑ Upgrade
Morgan Stanley • Brian Nowak 📅 2026-03-09
Equal Weight → Overweight
Old PT $680.00
New PT $750.00
Current $654.07
14.7%
Reality Labs inflection and advertising market share gains accelerating
XLE
Energy Select Sector SPDR
↑ Upgrade
JPMorgan • Christyan Malek 📅 2026-03-08
Neutral → Overweight
Old PT $58.00
New PT $65.00
Current $55.60
16.9%
Global supply constraints and energy security concerns driving structural repricing
AMD
Advanced Micro Devices, Inc.
↑ Upgrade
Jefferies • Mark Lipacis 📅 2026-03-07
Hold → Buy
Old PT $210.00
New PT $245.00
Current $203.23
20.5%
MI300 series ramping faster than expected, closing gap with NVIDIA in enterprise AI
TSLA
Tesla, Inc.
↑ Upgrade
Wedbush • Dan Ives 📅 2026-03-06
Neutral → Outperform
Old PT $420.00
New PT $485.00
Current $399.24
21.5%
FSD 13.0 breakthrough creating autonomous taxi platform value inflection
📉 Notable Downgrades 4 calls
ADBE
Adobe Inc.
↓ Downgrade
UBS • Karl Keirstead 📅 2026-03-10
Buy → Neutral
Old PT $320.00
New PT $285.00
Current $275.13
-3.6%
Generative AI disruption accelerating faster than Adobe's competitive response
CRM
Salesforce, Inc.
↓ Downgrade
Barclays • Raimo Lenschow 📅 2026-03-09
Overweight → Equal Weight
Old PT $225.00
New PT $200.00
Current $194.91
-2.6%
Enterprise software spending normalization pressuring growth and margins
ORCL
Oracle Corporation
↓ Downgrade
Credit Suisse • Phil Winslow 📅 2026-03-08
Outperform → Neutral
Old PT $165.00
New PT $152.00
Current $149.40
-1.7%
Cloud infrastructure competition intensifying, margin pressure mounting
NFLX
Netflix, Inc.
↓ Downgrade
Wells Fargo • Steven Cahall 📅 2026-03-07
Overweight → Equal Weight
Old PT $110.00
New PT $98.00
Current $96.94
-1.1%
Streaming market maturation and content cost inflation pressuring ROI
⚖️ Sector Weight Changes 4 changes
Goldman Sachs 📅 2026-03-09
Energy
↑ UPGRADED
Underweight → Neutral
Geopolitical risk premium and supply constraints creating multi-year tailwinds
Top Picks
XOMCVXCOP
Avoid
renewable energy names with extended payback periods
Morgan Stanley 📅 2026-03-08
Technology
↓ DOWNGRADED
Overweight → Neutral
Valuation reset needed as AI monetization timeline extends and competition intensifies
Top Picks
NVDAMSFTGOOGL
Avoid
unprofitable SaaS names facing margin pressure
JPMorgan 📅 2026-03-07
Industrials
↑ UPGRADED
Neutral → Overweight
Infrastructure spending and manufacturing reshoring creating multi-year capex cycle
Top Picks
CATDEGE
Avoid
construction names exposed to residential real estate
Barclays 📅 2026-03-06
Healthcare
↓ DOWNGRADED
Overweight → Neutral
Drug pricing pressure and biosimilar competition limiting growth visibility
Top Picks
JNJUNHABBV
Avoid
biotech names with binary clinical catalysts
🎯 Thematic Calls 4 themes
Sovereign AI Infrastructure
Goldman Sachs 📅 2026-03-05
BULLISH
Nation-state AI buildouts creating $500B+ incremental market as countries prioritize technological sovereignty
Beneficiaries
NVDAAMDTSM
At Risk
legacy datacenter REITs without AI-optimized facilities
Timeframe: 3-5 year structural trend | Conviction: HIGH
Quantum Computing Commercialization
Morgan Stanley 📅 2026-03-04
BULLISH
Error correction breakthroughs accelerating enterprise quantum adoption timeline to 2027-2028
Beneficiaries
IBMGOOGLIONQ
At Risk
traditional cybersecurity vendors unprepared for quantum threats
Timeframe: 2-3 year investment horizon | Conviction: MEDIUM
Energy Transition 2.0
JPMorgan 📅 2026-03-03
BULLISH
Next-generation battery tech and grid storage creating new winners beyond traditional renewables
Beneficiaries
TSLAENPHFSLR
At Risk
traditional utilities without storage infrastructure
Timeframe: 5-7 year secular trend | Conviction: HIGH
Biotech AI Drug Discovery
Barclays 📅 2026-03-02
BULLISH
AI-designed drugs showing 3x higher success rates in Phase II trials, compressing development timelines
Beneficiaries
GILDBIIBVRTX
At Risk
traditional CRO model being disrupted by AI platforms
Timeframe: 3-5 year clinical development cycle | Conviction: MEDIUM
🌍 Market Allocation
No allocation data
💡 Actionable Ideas 0 ideas
No actionable ideas